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ABSTRACT
Objective: The objective of this study was to determine CYP2D6 phenotype in a Javanese and Sundanese healthy subject in Indonesia.
Methods: Ninety unrelated healthy Indonesian subjects from Java and Sunda were studied. Metoprolol was used as phenotyping substrate. A 100 mg 
oral tablet of metoprolol was administered to all the subjects. Urinary metoprolol and α-hydroxymetoprolol were determined to calculate metoprolol 
metabolic ratio (MR). Determination of metoprolol and α-hydroxymetoprolol was carried out by high performance liquid chromatography method.
Results: Metoprolol MR varied widely (from 0.08 to 72.75). One subject (1.11%) in the study was classified as poor metabolizer (PM), one subject 
(1.11%) as ultrarapid metabolizer, and the remaining 88 subjects (97.78%) were classified as extensive metabolizers.
Conclusion: The frequencies of PM for the CYP2D6 phenotype (1.11%) in the Javanese and Sundanese population are in concordance with most 
results of oxidation metabolizers in other Asian populations.
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INTRODUCTION
CYP2D6, a minor form of CYP isoforms is only about 2% of the total CYP 
but has an important contribution in the metabolism of approximately 20–
25% of drugs used in the clinic, including β-blockers and antiarrhythmic 
agents. This enzyme activity catalyzes the Phase I reaction of drug 
metabolism which may determine the effects of the drug. Variability in 
drug metabolism between individuals often happens; the consequence is 
that at therapeutic doses may vary among individuals which, in turn, may 
result in adverse drug reaction or no therapeutic response. CYP2D6 along 
with CYP2C9 and CYP2C19 has a high polymorphism approximately 40% 
of Phase I hepatic metabolism. Phenotyping study of CYP2D6 enzyme 
activity can be measured in vivo after oral administration of a single dose 
of the drug which is a substrate of the enzyme. The urinary metabolic 
ratio (MR) between the parent drug and its metabolites was determined 
as an indicator of polymorphism [1-3].
Probes commonly used to measure the in vivo activity of CYP2D6 are 
debrisoquine, metoprolol, and dextromethorphan, but unfortunately 
debrisoquine not available for use in humans in many countries 
including Indonesia so that metoprolol can be used as a probe because 
it is not affected by changes of pH of urine [4].
Metoprolol is adrenoceptor antagonist (β-blockers) which has been 
used extensively for more than 25 years to treat cardiovascular 
disorders such as hypertension, arrhythmia, and heart failure [1,5]. 
Metoprolol has extensively experienced the first-pass metabolism 
so that the biological availability of only about 50% [6]. Specifically, 
CYP2D6 catalyzes the α-hydroxylation of metoprolol which produces 
metabolites α-hydroxymetoprolol [7]. A Pharmacokinetic study in the 
South Indian population showed variability in the plasma concentration 
of the drug after administration of metoprolol at standard doses [8].
In this study, the oxidation capacity of metoprolol in Indonesian healthy 
subjects is determined by determining the urinary MR of metoprolol 
and α-hydroxymetoprolol after single-dose administration of 100 mg 
metoprolol tartrate orally. Furthermore, the phenotype is determined 
whether including ultrarapid metabolizer (UM), extensive metabolizer 
(EM), intermediate metabolizer (IM), or poor metabolizer (PM).
MATERIALS AND METHODS
The study protocol was approved by the Health Research Ethics 
Committee of the Faculty of Medicine, Gadjah Mada University, 
Indonesia.
Materials
Metoprolol tartrate reference standard and caffeine used as internal 
standard were purchased from Sigma-Aldrich, St. Louis, MO, USA. 
α-Hidroksimetoprolol reference standard was purchased from Toronto 
Research Chemical. Acetonitrile and methanol (high-performance 
liquid chromatographic [HPLC] grade), sodium hydroxide, and 
orthophosphoric acid (analytical grade) were obtained from Merck and 
Co., Germany; 0.45 µm membrane filter, aqua bidestilata, and deionized 
water from PT. Otsuka, Japan, were used.
Methods
Subject
The study involved 90 Indonesian healthy subjects (19.58±1.47 years). 
All the participants were given the explanation and signed written 
informed consent to participate in the research. Volunteers are both 
man and woman from the Javanese and Sundanese. Volunteers in good 
health condition based on a physical examination, clinical laboratory 
tests which include liver and kidney function, examination of the heart 
electrocardiogram, and no history of serious illness, do not have a history 
of liver and kidney disorders, weight within the normal range. Exclusion 
criteria: Smokers: Women who use oral contraceptives, pregnant and/or 
lactating women, obesity, a history of gastrointestinal disorders, she has 
a history of dependence on alcohol or drug abuse, are taking metoprolol, 
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contraindications or hypersensitivity to metoprolol sinus bradycardia, 
cardiogenic shock and heart failure, a history of bronchospasm or 
asthma, heart rate <45 beats/min, heart block Grade 2 and 3, systolic 
blood pressure <100 mmHg, or heart failure moderate to heavily.
Phenotype Study of CYP2D6 using metoprolol
The subjects were not allowed to take any medication or consume 
alcoholic beverages and drinks/foods containing caffeine for 1 week before 
administration. The subjects received a single dose of metoprolol tartrate 
tablets (100 mg) orally with 200 mL of water after overnight fasting before 
administration of the drug. Urine was collected for 8 h from the time taking 
metoprolol tablets. Urine samples were stored at −40°C before analysis.
Liquid–liquid extraction was performed using dichloromethane 
solvent after the addition of sodium hydroxide into the urine sample. 
The reversed-phase HPLC method [9] was slightly modified and used 
for the determination of α-hydroxymetoprolol and metoprolol in 
urine samples. Separation was carried out in a Purospher® STAR RP-
18e LiChroCART® (250×4.6 mm, 5 µm) column with a mobile phase 
consisting of a mixture of 25 mM KH2PO4 solution (pH was adjusted into 3 
with orthophosphoric acid)-acetonitrile-methanol (70:15:15, v/v) with 
a flow rate of 1 ml/min and injection volume of 20 µl. The Ultraviolet 
detector was set at λ 234 nm. Quantification of α-hydroxymetoprolol 
and metoprolol was performed using internal standard caffeine.
Urinary metoprolol and α-hydroxymetoprolol were determined to 
calculate metoprolol MR. Based on the MR (or LogMR) value, the 
phenotype of the test subjects was classified as a PM with MR >12.6 
(LogMR >1.1), IM and EM with 0.1 <MR <12.6 (−1.0 <LogMR <1.1), and 
UM with MR <0.1 (LogMR <−1.0).
Data analysis
CYP2D6 enzyme activity was determined by determining the ratio of 
the molar concentration of metoprolol/α-hydroxymetoprolol in the 
urine. The ratio of metoprolol and α-hydroxymetoprolol in the urine 
(MR) was calculated by the following equation:
MR=(metoprolol)/(α-hydroxymetoprolol)
The phenotype was determined by the MR. Subjects with MR >12.6 
were classified as PM, subjects with MR 0.1–12.6 were classified as IM 
and EM, and subjects with MR <0.1 were classified as UM [10].
RESULTS AND DISCUSSION
Characteristics of the subjects who participated in this study can be 
shown in Table 1. In this study, factors that can change the absorption, 
distribution, metabolism, and excretion of the drug are controlled. 
These factors include age, pregnancy, ethnicity, pathological conditions, 
obesity, consumption of drugs or other compounds, and time of 
administration of the drug.
The MR value of the subjects had a very wide range (from 0.08 to 
72.75). MR distribution patterns are displayed as a histogram in Fig. 1. 
As shown in the histogram, the distribution of MR showed the presence 
of three different phenotypes. A clear-cut point between 9.84 and 72.75 
MR value was 12.6 (anti-mode). To determine metabolizer status to 
metoprolol, 12.6 is used as anti-mode [11]. Anti-mode for debrisoquine 
and metoprolol has proved equally on studies for the Turkish population 
and the other Caucasian population [12].
Based on the phenotyping study, there are differences in the 
hydroxylation capacity of metoprolol in the Javanese and Sundanese 
healthy subjects groups (Table 2). Metoprolol MR varied widely. The 
MR data are in the range from 0.1 to 74.9 with a median of 1.3. The 
LogMR value range is −1.1–1.9 with a median of 0.1. One subject from 
Sundanese women (1.11%) in the study was classified as PM, one 
subject from Javanese women (1.11%) as UM, and the remaining 88 
subjects (97.78%) were classified as EM.
There is no evidence of significantly different between the subjects for 
the LogMR value between Javanese and Sundanese subjects based on 
the Mann–Whitney U-test (p>0.05). LogMR and MR values mostly are 
above the median value either for women test subjects or men. This 
illustrates that the metoprolol metabolism capacity of the women and 
men subject, in general, is similar.
The results of this study are different from the previous studies. Studies 
with CYP2D6 substrate, especially dextromethorphan, showed that in 
EM individuals, there was a shift in the value of dextromethorphan/
dextrorphan MR for female subjects compared to MR values in male 
subjects. The CYP2D6 activity in male subjects was higher than in 
female subjects [13]. The results of studies on other CYP2D6 substrates 
such as metoprolol, sertraline, mirtazapine, and propranolol showed 
that CYP2D6 activity was higher in male subjects than in female 
subjects [14].
Fig. 1: Histogram of metoprolol/α-hydroxymetoprolol metabolic 
ratio from Javanese and Sundanese healthy subjects (n=90)
Table 2: CYP2D6 phenotype data
Metabolic ratio metoprolol/α-hydroxymetoprolol Phenotype Number of subjects Percentage (%)
MR<0.1 Ultra rapid metabolizer 1 1.11
0.1<MR<12.6 Extensive metabolizer 88 97.78
MR>12.6 Poor metabolizer 1 1.11
Total 90 100
MR: Metabolic ratio
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The frequencies of PM for the CYP2D6 phenotype (1.11%) in this 
study are in concordance with most results of oxidation metabolizers 
in other Asian populations. The prevalence of PM in the Japanese 
population range from 0.3 to 0.5% in the Malaysian subjects amounted 
to 3.9% [15], in the Iran subject of at 2.5%. CYP2D6 phenotyping study 
has been reported using metoprolol substrate or other substrates such 
as dextromethorphan, debrisoquine, and sparteine with consistent 
results that the presence of PM is low in Asian populations such 
as Japan, China, Korea, Malaysia, and Iran. Using debrisoquine as a 
substrate, PM on Malaysia’s population is 3.9% [15]. Using metoprolol 
as the substrate, the frequency of PM population in Korea, Japan, and 
China was 0.5%, 0.7%, and 0%, respectively [16]. The existence of 
PMs individual in Indonesian subjects (1.11%) is lower than PMs 
in European and American countries (Caucasian individuals) such 
as the population of Britain (8.4%) [17], Czech (8.7%), and German 
(8.7%) [18], Uruguay (7.3%) [19], and Mexico (10%) [20] and African 
countries such as Zimbabwe (5%) [11] and Nigeria (3.5%) [21].
The probit plot (Fig. 2) of the LogMR of all subjects shows a multimodal 
distribution profile. The plot also clarifies the existence of three 
phenotypes of the hydroxylation capacity of metoprolol. Fig. 1 shows 
that the mode value of the LogMR is −0.1. The mode values in this 
Indonesian subjects are shifted to the right when compared to Japanese 
subjects (mode: −0.8) and shifted to the left when compared to Chinese 
subjects (mode: 0.7) [22]. This shows that the hydroxylation capacity 
of Indonesian subjects is stronger than Japanese subjects but is weaker 
than Chinese subjects.
This polymorphism of CYP2D6 among Javanese had similarity with 
the polymorphism of CYP2A6 among the same genetic ethnic of 
Javanese [23]. Genetically, CYP2A6*4 was found higher compared to the 
occurrence of CYP2A6*1 among smoking and non-smoking subject. The 
distribution of these allele frequencies was different among those two 
types of subjects.
The MR data in the CYP2D6 phenotyping study using dextromethorphan 
as the substrate in the Chinese population (120 people) showed a 
bimodal distribution and about 36% of subjects were classified as 
IM [24]. However, the MR value in this phenotyping study involving 90 
subjects has not been able to distinguish the extensive and IM.
CONCLUSION
Indonesian healthy subjects have different capacities to metabolize 
metoprolol through CYP2D6. The frequency of PM of CYP2D6 
phenotype (1.11%) in the Javanese and Sundanese is in conformity and 
comparable to other Asian populations. This study has not been able to 
identify IM. It needs the additional study using more subjects. Further 
study was needed to determine the CYP2D6 genotype in Javanese and 
Sundanese populations. The results of this study might be helpful in 
patient dose adjusting to achieve the therapeutic goals.
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